☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
BMS
BMS Highlights Data from the P-I/II Study of Krazati Plus Cetuximab to Treat Locally Advanced or Metastatic Colorectal Cancer at t...
April 9, 2024
BMS Highlights Pooled Interim Data from the P-III (EMERGENT) Program of KarXT for Schizophrenia at the SIRS 2024
April 8, 2024
BMS Reports the EC’s Expanded Approval of Reblozyl as a 1L Treatment of Transfusion-Dependent Anemia Due to Myelodysplastic Syndro...
April 3, 2024
BMS’ Abecma Receives EC’s Approval for the Treatment of Relapsed/Refractory Multiple Myeloma
March 21, 2024
PharmaShots Weekly Snapshots (March 11 – March 15, 2024)
March 15, 2024
BMS’ Breyanzi Receives the US FDA’s Approval for the Treatment of R/R Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymp...
March 15, 2024
Load more...
Back to Home